滤泡性淋巴瘤的临床特征及预后因素分析

目的观察滤泡性淋巴瘤的临床特征,并对可能影响其预后的相关因素进行分析。方法回顾性分析2009年3月至2013年7月间70例滤泡性淋巴瘤患者的临床资料,观察其临床特征,并对预后可能产生影响的患者自身因素和各项临床指标进行单因素和多因素的分析。结果滤泡性淋巴瘤最常见的临床症状为无痛性淋巴结肿大,任何器官都可以涉及。单因素分析结果显示,临床分期、结外病灶数目、B症状、PS评分与预后密切相关。多因素分析结果显示,临床分期、PS得分、结外病灶数目、D20单克隆抗体治疗是滤泡性淋巴瘤患者预后的影响因素。结论对滤泡性淋巴瘤的预后产生影响的因素有很多种,应该根据不同患者的情况,合理调控不同因素对患者可能产生的影响。     

不同年龄组低级别滤泡淋巴瘤的临床特征及预后分析

目的:分析低级别滤泡淋巴瘤(follicular lymphoma,FL)在各年龄段人群中的临床特征及预后。方法:收集2011年1月至2019年12月郑州大学第一附属医院初治的82例低级别FL患者的病例资料,男女比为1∶1.05,中位年龄52(19～84)岁。分类变量行Chi-square检验,采用Kaplan-Meier法、Logistic单因素分析及Cox回归模型多因素分析进行生存资料分析。结果:82例患者分为年龄<40岁、40～59岁和≥60岁3个组。随着年龄段的上升,患者多见红细胞沉降率(erythrocyte sedimentation rate,ESR)增快、外周血血小板与淋巴细胞比值(platelet to lymphocyte ratio,PLR)升高、Bcl-2表达呈阳性的患者比例升高、ECOG评分和FLIPI-2评分升高,且初治效果达到完全缓解(complete response,CR)的比例降低(P<0.05)。随访的73例患者2、5年总生存率(overall survival,OS)分别为97.2%和74.1%,无进展生存率(progression-...     

滤泡性淋巴瘤预后因素的研究

滤泡性淋巴瘤(follicular lymphoma,FL)是一种起源于滤泡生发中心B细胞的淋巴瘤,其发病率在美国和西欧最高,而在亚洲和发展中国家的发病率相对较低。FL主要累及淋巴结,通常表现为无痛性多发淋巴结肿大。原发于淋巴结外的FL常见于胃肠道、软组织、乳腺及眼眶附属器。FL患者多表现为惰性临床过程,总生存率较高,但多数患者仍会复发或进展。回顾FL的预后因素,为指导患者的临床治疗提供理论依据。     

滤泡性淋巴瘤预后因素的研究进展

滤泡性淋巴瘤(follicular lymphoma,FL)是一组在生物学特征、临床表现及预后等方面存在高度异质性的血液肿瘤,多种因素影响其预后。既有的FL预后模型,包括滤泡淋巴瘤国际预后指数(follicular lymphoma international prognostic index,FLIPI)、FLI PI-2等主要强调基线临床及实验室检查特点对预后的影响,且价值有限。近年来随着分子影像学、基因测序等现代技术的发展,肿瘤代谢负荷参数、分子生物学特征(如肿瘤微环境特点、表观遗传学改变等)等在FL预后预测方面的价值逐渐被挖掘,尤其与既有临床预后指数结合(如包含7个基因突变情况的临床遗传学风险模型m7-FLIPI)时更是提高了预测的准确性。除基线预后因素外,FL治疗反应的预后价值也是近年来研究的热点。本文根据国内外研究进展,从组织学特点、肿瘤代谢负荷、基于临床特征建立的预后模型、肿瘤微环境、治疗反应、分子遗传学特征等方面对影响FL患者预后的因素进行综述。     

滤泡性淋巴瘤的临床特点、预后及治疗

 滤泡性淋巴瘤的发生率居非霍奇金淋巴瘤发病率的第二位,临床上疾病发展呈惰性,主要表现为无痛性淋巴结肿大。预后因素包括滤泡淋巴瘤国际预后指数（FL IPI）、肿瘤组织免疫微环境。免疫化疗已成为滤泡淋巴瘤的一线治疗方法,滤泡淋巴瘤一经诊断即应开始治疗,观察等待策略仅限于少数选择病例。造血干细胞移植适用于复发、难治的病例。     

西部单中心51例套细胞淋巴瘤患者临床特征及预后因素分析

目的:研究套细胞淋巴瘤（MCL)患者的临床特点及预后相关因素,进一步全面评估病情,探索个体化治疗。方法:回顾性分析2012年1 月至2016年12 月经我院病理科确诊的51例MCL 患者的临床特点、住院20例患者的预后分层和不同化疗方案的近期及远期疗效,并进行随访观察。结果:20例住院治疗患者中,R-Hyper-CVAD组及R-CHOP样组的ORR（分别为100%、100%）均高于其未联合美罗华组（分别为50%、40%）;MIPI评分中,低危组ORR为75.0%,明显高于中危组（16.6%）;CD5-患者CR、PR均高于CD5+患者;Ki67≥30%患者CR率（20%）大于Ki67＜30%组（11%）,PR率则相反;Ki67＜30%患者3年OS明显高于Ki67≥30%患者,有统计学差异,而PFS无统计学差异;MIPI分组中,低危组3年OS明显高于中高危组,有统计学差异,PFS无统计学差异;美罗华组无论OS还是PFS均高于非美罗华组;Hyper-CVAD组与非Hyper-CVAD组OS、PFS均无统计学差异。结论:美罗华联合化疗治疗MCL的疗效是肯定的,绝大多数患者能够耐受减低剂量的Hyper-CVAD A及B方案化疗,但统计学显示与非Hyper-CVAD组无明显差异,可能与病例数偏少相关,需要更多大样本的循证医学的支持。     

早期复发 进展滤泡性淋巴瘤的预后及危险因素分析

目的:探讨滤泡性淋巴瘤(follicular lymphoma,FL)患者中确诊后24个月内疾病进展(progression of disease within 24months,POD24)的发生率、预后价值及危险因素。方法:回顾性分析2010年1月至2015年12月于天津医科大学肿瘤医院接受化疗的140例初治FL患者的临床及随访资料,行免疫组织化学检测其中75例治疗前肿瘤组织中Myc、Bcl-2和Bcl-6等的表达情况。采用Kaplan-Meier曲线及Cox回归模型分析POD24对预后的影响,应用Logistic回归模型分析POD24的危险因素并构建预测模型。结果:140例初治FL患者中有42例(30%)发生POD24。Kaplan-Meier分析示,POD24组的总生存(overall survival,OS)显著差于非POD24组(P<0.001);Cox单因素及多因素分析显示,POD24为OS最显著的独立预后因素(HR=8.386,P<0.001)。一线治疗方案校正的单因素Logistic回归分析显示,脾脏受累、FL国际预后指数(follicular lymph...     

滤泡淋巴瘤的预后与治疗的研究进展

摘 要：滤泡性淋巴瘤（FL）是一种起源于滤泡生发中心的惰性非霍奇金淋巴瘤,患者具有高复发率、短暂持续缓解时间和高转化率的特点。在疾病早期预测滤泡淋巴瘤患者的疾病风险,对于疾病的预后及治疗至关重要。全文探讨滤泡淋巴瘤的各种临床预后标志物及该病治疗的最新进展。     

青海地区淋巴瘤253例临床特点与预后因素分析

目的 分析淋巴瘤的临床特点及预后相关因素.方法 对青海地区253例淋巴瘤患者临床资料进行回顾性研究并随访.采用Kaplan-Meier法分析患者不同临床特点及实验室检查的生存期差异.采用Cox比例风险回归模型分析影响预后的因素.结果 253例淋巴瘤患者中,男、女比例为1.56∶1,中位年龄为48岁,发病年龄高峰为40岁和60岁左右.结内起病（56.13％）较多,结外起病常见部位为鼻咽部和胃肠道.病理类型为霍奇金淋巴瘤40例（15.81％）,非霍奇金淋巴瘤213例（84.19％）.前者以结节硬化型（72.50％）最多见;后者中B细胞淋巴瘤148例（69.48％）,最常见的病理类型为弥漫大B细胞淋巴瘤（39.91％）、滤泡细胞淋巴瘤（12.21％）及周围T细胞非特殊型淋巴瘤（9.39％）.单因素预后分析显示,临床分期、有无B症状、血红蛋白（Hb）、乳酸脱氢酶（LDH）、国际预后指数（IPI）及治疗方案与非霍奇金淋巴瘤预后密切相关（均P＜0.05）.Cox回归模型多因素分析显示,临床分期、IPI及治疗方案与非霍奇金淋巴瘤的预后关系密切,差异有统计学意义（均P＜0.05）.结论 青海地区淋巴瘤发病年龄有两个高峰,结内发病高于结外,B细胞淋巴瘤多见,IPI分组适用于该地区非霍奇金淋巴瘤的预后评估,并可作为其独立的预后因素.     

Survival after progression in patients with follicular lymphoma: analysis of prognostic factors.

BACKGROUND: The purpose of this study was to identify prognostic parameters for patients with follicular lymphoma (FL) in first progression/relapse. These would be useful for selection of high-risk patients for inclusion in trials aimed at determining the effect of new treatment approaches in such patients. PATIENTS AND METHODS: Ninety patients (48 male, 42 female, median age 56 years) diagnosed with FL, in a single institution during a 20 year period and relapsing/progressing after an initial response to therapy, were recruited. The main end-point of the study was survival from progression (SFP). Univariate and multivariate analyses were performed, including among the predictive variables the response duration (RD) after the initial treatment and the main features of the patients at the first progression or relapse. RESULTS: Five-year SFP was 47% (95% confidence interval 35% to 58%). Patients with RD following initial therapy >2 years had a longer SFP (5-year SFP 63 versus 33%, P = 0.012). Other variables with prognostic interest for SFP were stage at diagnosis and the following variables at relapse: age, bulky disease, performance status, serum lactate dehydrogenase level, serum beta2-microglobulin level, bone marrow involvement, stage and International Prognostic Index rating. In the multivariate analysis, poor performance status at progression and a RD <2 years were the most important unfavorable variables to predict SFP. CONCLUSION: In patients with FL, RD along with performance status at progression are features that predict SFP. These variables could thus be useful to select candidates for experimental treatments.     

Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems.

BACKGROUND: The International Prognostic Index (IPI), initially designed for aggressive lymphomas, is also used in follicular lymphoma (FL) and other indolent lymphomas. Two new prognostic indexes have recently been proposed for FL [the Italian Lymphoma Intergroup (ILI) Index and the Follicular Lymphoma International Prognostic Index (FLIPI)]. PATIENTS AND METHODS: Three indexes, IPI [age >60 years, extranodal involvement two or more sites, elevated lactate dehydrogenase (LDH), Eastern Cooperative Oncology Group performance status > or =2, stage > or =3], ILI (age >60 years, extranodal involvement two or more sites, elevated LDH, male sex, B symptoms, erythrocyte sedimentation rate > or =30 mm first hour) and FLIPI (age >60 years, stage > or =3, elevated LDH, nodal involvement five or more, haemoglobin level < or =12 g/dl) were calculated in 411 patients with FL. RESULTS: Overall concordance between the three indexes was 54%. A total of 126 (31%) patients were included in the high-risk group according to IPI, 131 (32%) according to ILI and 157 (38%) after FLIPI application. Ten-year overall survival rates after applying the prognostic indexes (IPI, ILI and FLIPI) were, respectively: 72%, 71% and 72%, in the low-risk group; 51%, 60% and 49% in the intermediate-risk group; and 24%, 16% and 31% in the high-risk group. CONCLUSIONS: In this series, all three indexes, IPI, ILI and FLIPI, were useful to classify FL patients into differentiated risk groups, although the FLIPI identified a larger proportion of high-risk patients than the IPI and ILI.     

Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin's lymphoma registry.

BACKGROUND: The influence of age on the outcome of follicular non-Hodgkin's lymphoma (FL) was studied in a population-based non-Hodgkin's lymphoma registry. PATIENTS AND METHODS: This study comprised 214 follicular lymphoma patients. Grade I/II was considered separately from grade III FL. The data were analyzed with respect to three age groups: <60, 60-69 and >or=70 years. RESULTS: The overall survival rate decreased in the older age groups. Grade III patients showed a statistically significant decrease in overall survival in comparison with grade I/II patients (P = 0.03). Cause-specific survival analysis showed that in the older age groups, there was an increasing influence of concomitant disease on the death rate, especially among grade III FL patients >70 years of age. The survival curve in grade III FL patients was shown to reach a plateau. The prognostic scoring system, according to the Italian Lymphoma Intergroup, fitted better to grade I/II patients, while the International Prognostic Index showed better discrimination amongst grade III patients. CONCLUSIONS: Separate grading for follicular lymphoma is useful. An age >70 years has a negative impact on outcome, but the contribution of concomitant disease herein is important. Different prognostic scoring systems should be applied to the different grades of FL.     

胃肠道间质瘤临床特征及预后影响因素分析

目的:探讨胃肠道间质瘤临床特征及预后影响因素。方法:回顾性分析我院2011年3月至2014年1月收治的653例胃肠道间质瘤患者临床资料,归纳临床特征,采用统计学方法分析影响预后的危险因素。结果:男女性别比为1.17∶1,年龄分布以40岁以上人群为主(84.07%)。首发症状以消化道出血(37.98%)、腹痛及腹胀(32.01%)、消化道症状(14.85%)为主,部分患者无明显症状(4.44%)。肿瘤发生部位以小肠(20.06%)和胃部(58.35%)为主。581例(88.97%)患者行根治性切除,72例(11.03%)患者行姑息性切除。根治性手术患者中,137例(20.98%)患者行联合脏器切除。112例(17.15%)患者行淋巴结清扫,淋巴结清扫数平均为(23.45±6.12)枚。63例患者术后采用伊马替尼（400 mg/d）口服治疗。371例(56.81%)患者核分裂象≤5个/50 HPF,282例(43.18%)患者核分裂象＞5个/50 HPF。CD117阳性581例(88.97%),S-100阳性61例(9.34%),CD34阳性568例(86.98%)。患者1年、3年及5年总体生存率为96.71%、76.52%和61.83%。单因素分析发现核分裂象、肿瘤最大径、手术根治性及改良NIH危险度分级与胃肠道间质瘤患者5年生存率有关,多因素回归分析证实以上因素是影响患者5年生存率的独立危险因素(P＜0.05)。结论:胃肠道间质瘤主要分布在40岁以上人群,但临床症状不典型,可通过核分裂象、肿瘤最大径、手术根治性及改良NIH危险度分级评估预后。     

15例腺泡状软组织肉瘤临床特点及预后分析

背景与目的：腺泡状软组织肉瘤（alveolar soft part sarcoma,ASPS@是一种罕见的恶性软组织肿瘤,生长缓慢,无典型临床症状,常伴有远处转移（肺转移,脑转移及骨转移等@。本文旨在研究腺泡状软组织肉瘤的临床特点,评估其预后因素。方法：回顾性研究了2003年1月-2008年12月就诊于北京大学人民医院骨与软组织肿瘤治疗中心的15例腺泡状软组织肉瘤患者的临床资料,并随访了他们的预后情况。15例患者中,女性9例,男性6例;小于或等于30岁者8例,大于30岁7例;肿瘤大于5cm者11例,小于5cm者4例;原发于软组织12例,原发于骨骼3例;未见其他部位转移6例,肺转移6例,骨转移3例,脑转移2例;术后局部复发2例;术后9例接受放疗,6例未接受放疗;术后接受化疗11例,未接受化疗4例,化疗方案MAID：多柔比星,氮唏米胺及异环磷酰胺。结果：患者预后情况较差,其中无瘤生存6例,带瘤生存4例,死亡5例,中位生存时间为42.0个月,5年生存率为41.7%。伴有远处转移（肺转移、脑转移及骨转移@的患者5年生存率远低于整体生存率。患者个人性别、年龄对预后无显著性差异。肿瘤大小、部位及有无远处转移是影响预后的重要因素。结论：腺泡状软组织肉瘤是高度恶性软组织肿瘤。尽早评估病情,制定合适的治疗方案,原发病灶采取广泛切除,以降低复发及转移风险。但由于本组数据较少,放化疗是否有效还需进一步研究。     

Prognosis of follicular lymphomas

Follicular lymphoma (FL) is as an indolent neoplasia with median survival measured in decades. Nevertheless, some patients have poor progression-free survival and overall survival. Several treatment approaches are proposed for patients with FL, however criteria to rationalize treatment decisions are lacking. Studies have been performed to build up prognostic indices that are useful for defining risk-adapted treatment recommendations. Available indices are based on parameters that have an independent role in predicting patient survival and that are variably correlated with the features of the disease, with the characteristics of the patient and with the effects of treatment. Two new prognostic indices have recently been proposed for FL: the Italian Lymphoma Intergroup (ILI) index and the Follicular Lymphoma International prognostic Index (FLIPI). Both indices are based on large series of patients and exhibit differences in their ability to discriminate between patients with different probabilities of survival. In recent years, with the advent of gene expression profile studies, our knowledge of the biology of FL is changing as novel data become available about the lymphoma cell and about the role of the microenvironment; these studies have already provided novel prognostic tools for identifying patients with more aggressive disease. Further data and large international cooperative studies are needed to translate into clinical practice the novel acquisitions of biology and therapeutics.     

嗜铬细胞瘤/副神经节瘤骨转移临床特征及危险因素分析

目的:探讨嗜铬细胞瘤/副神经节瘤（pheochromocytoma/paraganglioma,PPGLs）术后骨转移患者的临床特征及早期（术后2年内）发生骨转移的危险因素。方法:收集60例初诊为PPGLs术后骨转移患者的临床资料并分析骨转移的危险因素及骨转移灶的分布差异。结果:60 例PPGLs患者单发骨转移14 例（23.3%）,多发者46 例（76.7%）。发生骨转移的中位时间为 84 个月,早期骨转移者 15 例（25%）。单因素分析示PPGLs患者的年龄与早期骨转移有关（χ2=6.207,P=0.045）。早期骨转移中年龄＜60岁者多见,差异有统计学意义（χ2=25.600,P=0.000）。PPGLs共发现骨转移灶 353处,其中胸椎转移 79 处。27例（45.0%）患者出现骨转移相关并发症,依次为骨痛（88.9%）、麻木（51.9%）、骨折（37.0%）、瘫痪（11.1%）及高钙血症（3.7%）。结论:PPGLs患者的年龄与早期骨转移有关,年龄＜60岁者发生早期骨转移多见,绝大多数骨转移发生在手术 2年以后。PPGLs骨转移灶通常为多发,其中以胸椎转移最为常见。骨转移相关并发症最常见为骨痛。